Antibody dependent disease enhancement (ADE) after COVID-19 vaccination and beta glucans as a safer strategy in management.

Authors:
Ikewaki N; Kurosawa G; Levy GA; Preethy S; Abraham SJK.

Journal:
Vaccine

Publication Year: 2023

DOI:
10.1016/j.vaccine.2023.03.005

PMCID:
PMC9992059

PMID:
36906407

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Vaccine

Abbreviation: Vaccine

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Long-term surveillance of invasive pneumococcal disease: The impact of 10-valent pneumococcal conju…
Reis JN; Azevedo J; de Oliveira AML and 11 more (2024) - Transparency Score: 3/6
Advances in intranasal vaccine delivery: A promising non-invasive route of immunization.
Kehagia E; Papakyriakopoulou P; Valsami G. (2023) - Transparency Score: 2/6
A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing …
Baek YJ; Kim WJ; Ko JH and 11 more (2023) - Transparency Score: 4/6
A humanized monoclonal antibody targeting protein a promotes opsonophagocytosis of Staphylococcus a…
Bernardino PN; Bhattacharya M; Chen X and 3 more (2023) - Transparency Score: 3/6
Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data…
Maltezou HC; Hatziantoniou S; Theodoridou K and 3 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Author Samuel Abraham is a shareholder in GN Corporation, Japan which holds shares of Sophy Inc., Japan, the manufacturers of novel beta glucans using different strains of Aureobasidium pullulans; a board member in both the companies and also an applicant to several patents of relevance to these beta glucans."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025